Company: SCLXW
Filing Date: 2025-02-27
Form Type: DEF 14A
Source: 0001193125-25-039223
Chunk: 39

Company: Scilex Holding Co
Filing Date: 2025-02-27
Form: DEF 14A
Chunk 39
---
 held by Dr. Ji’s spouse and an aggregate of 292,264 shares held by family trusts for the benefit of Dr. Ji, his spouse and 
 his children.                                                                                                                                                                                                                       |

| (4) | Represents 360,569 shares subject to options exercisable within 60 days of January 31, 2025 and 22,840 
 shares held directly.                                                                                  |

| (5) | Represents 101,041 shares subject to options exercisable within 60 days of January 31, 2025, 112,500 
 shares held directly and 11 shares held by Dr. Chun’s child.                                         |

| (6) | Represents 195,192 shares subject to options exercisable within 60 days of January 31, 2025 and 2,300 
 shares held directly.                                                                                 |

| (7) | Represents 36,457 shares subject to options exercisable within 60 days of January 31, 2025. |

| (8) | Represents 505,139 shares subject to options exercisable within 60 days of January 31, 2025 and 25,000 
 shares held directly.                                                                                  |

| (9) | Represents (a) 51,039,214 shares of Common Stock held directly and (b) 490,617 shares underlying SPAC                                                                                                                                                                                                                                   
 Warrants (as defined in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 12, 2024 (the “Form 10-K”)), all of which are currently exercisable, in each case, transferred to SCLX JV in connection with the Equity Repurchase Transaction (as defined in the Form 10-K). 
 Does not include any shares of Series A Preferred Stock. The voting and dispositive power of the equity securities of the Company (including the Series A Preferred Stock) held by SCLX JV are subject to the control of an independent manager, Jack Wu,                                                                               
 until such time as the Oramed Note and any Additional Notes (each as defined in the Form 10-K) are paid in full. The business address of SCLX Stock Acquisition JV LLC is 960 San Antonio Road, Palo Alto, CA                                                                                                                           
 94303.                                                                                                                                                                                                                                                                                                                                  |

| (10) | The ownership information for Oramed Pharmaceuticals Inc. (“Oramed”) is based on information                                                                                                                                                           
 supplied by Oramed in a statement